

C. diff. Spores and More Tuesday at 10 AM Pacific February 23rd 2016: Ecobiotics- A Novel Approach to Recurrent C. difficile infections

This episode introduces Seres Therapeutics, a leading microbiome therapeutics company, which recently published in the Journal of Infectious Diseases positive results from an open-label Phase 1b/2 study of SER-109 for the treatment of patients with recurrent C. difficile infections (CDI). Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibili

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel



Questions? Comments? Call In Live! Call-In Toll Free: 1-866-472-5792 Intl: 001-480-553-5759

Read more





throughout his career.

Featured Guests



David Cook, Ph.D David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry



Michele (Shelley) Trucksis, Ph.D, M.D

Michele (Shelley) Trucksis is the Executive Vice President and Chief Medical Officer of Seres Therapeutics, Inc. ("Seres"). Dr. Trucksis has 25 years of experience in medicine and infectious diseases. Prior to joining Seres, she served as Executive Director of Merck Research Laboratories with responsibility for clinical and global product development functions and development strategy in antibacterials, antifungals, and anti-cytomegalovirus drug candidates.

Read more

\${item.GetBioByLength(700).Replace("&","&")}

Read more

Share This Episode







Connect with VoiceAmerica



















Read what our hosts are writing about.

